男性BRCA1/2突变携带者的前列腺癌风险:前瞻性队列研究
这项前瞻性队列研究随访了英国和爱尔兰的376名男性BRCA1携带者和447名BRCA2携带者,评估其前列腺癌相对与绝对风险。BRCA2携带者前列腺癌风险显著升高且与侵袭性前列腺癌相关,BRCA1携带者关联较弱且受筛查效应影响。
要点
- BRCA2携带者前列腺癌风险显著升高,85岁前绝对风险达60%。
- BRCA2突变与更高Gleason评分和前列腺癌死亡风险相关。
- BRCA1携带者风险关联较弱,且受潜在筛查效应影响。
核心结论
- BRCA2携带者前列腺癌风险高,尤其侵袭性前列腺癌,风险随家族史和突变位置变化。
- BRCA1携带者前列腺癌关联较弱,结果受筛查效应影响。
研究设计与样本
- 前瞻性队列研究,纳入英国和爱尔兰临床遗传中心的男性BRCA1携带者376例和BRCA2携带者447例。
- BRCA1和BRCA2携带者的中位随访时间分别为5.9年和5.3年。
主要发现
- BRCA2携带者的标准化发病比为4.45(95%CI 2.99-6.61),75岁和85岁前绝对风险分别为27%(95%CI 17-41%)和60%(95%CI 43-78%)。
- BRCA1携带者总体标准化发病比为2.35(95%CI 1.43-3.88),65岁以下标准化发病比为3.57(95%CI 1.68-7.58),但敏感性分析中标准化发病比在0.74至2.83之间变化。
- BRCA2携带者前列腺癌风险随家族史增加(每增加一名受累亲属的HR为1.68,95%CI 0.99-2.85)。
- BRCA2突变位于c.2831至c.6401区域的标准化发病比为2.46(95%CI 1.07-5.64),该区域突变相比区域外突变的前列腺癌风险更低(HR 0.37,95%CI 0.14-0.96)。
临床怎么用
- 对BRCA2携带者应加强前列腺癌筛查和风险评估,考虑家族史和突变位置。
- BRCA1携带者的前列腺癌风险需结合筛查效应个体化评估。
局限性
- 已知突变携带者可能存在潜在筛查效应,但BRCA2结果在多项敏感性分析中稳健。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: BRCA1 and BRCA2 mutations have been associated with prostate cancer (PCa) risk but a wide range of risk estimates have been reported that are based on retrospective studies. OBJECTIVE: To estimate relative and absolute PCa risks associated with BRCA1/2 mutations and to assess risk modification by age, family history, and mutation location. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective cohort study of male BRCA1 (n = 376) and BRCA2 carriers (n = 447) identified in clinical genetics centres in the UK and Ireland (median follow-up 5.9 and 5.3 yr, respectively). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Standardised incidence/mortality ratios (SIRs/SMRs) relative to population incidences or mortality rates, absolute risks, and hazard ratios (HRs) were estimated using cohort and survival analysis methods. RESULTS AND LIMITATIONS: Sixteen BRCA1 and 26 BRCA2 carriers were diagnosed with PCa during follow-up. BRCA2 carriers had an SIR of 4.45 (95% confidence interval [CI] 2.99-6.61) and absolute PCa risk of 27% (95% CI 17-41%) and 60% (95% CI 43-78%) by ages 75 and 85 yr, respectively. For BRCA1 carriers, the overall SIR was 2.35 (95% CI 1.43-3.88); the corresponding SIR at age <65 yr was 3.57 (95% CI 1.68-7.58). However, the BRCA1 SIR varied between 0.74 and 2.83 in sensitivity analyses to assess potential screening effects. PCa risk for BRCA2 carriers increased with family history (HR per affected relative 1.68, 95% CI 0.99-2.85). BRCA2 mutations in the region bounded by positions c.2831 and c.6401 were associated with an SIR of 2.46 (95% CI 1.07-5.64) compared to population incidences, corresponding to lower PCa risk (HR 0.37, 95% CI 0.14-0.96) than for mutations outside the region. BRCA2 carriers had a stronger association with Gleason score ≥7 (SIR 5.07, 95% CI 3.20-8.02) than Gleason score ≤6 PCa (SIR 3.03, 95% CI 1.24-7.44), and a higher risk of death from PCa (SMR 3.85, 95% CI 1.44-10.3). Limitations include potential screening effects for these known mutation carriers; however, the BRCA2 results were robust to multiple sensitivity analyses. CONCLUSIONS: The results substantiate PCa risk patterns indicated by retrospective analyses for BRCA2 carriers, including further evidence of association with aggressive PCa, and give some support for a weaker association in BRCA1 carriers. PATIENT SUMMARY: In this study we followed unaffected men known to carry mutations in the BRCA1 and BRCA2 genes to investigate whether they are at higher risk of developing prostate cancer compared to the general population. We found that carriers of BRCA2 mutations have a high risk of developing prostate cancer, particularly more aggressive prostate cancer, and that this risk varies by family history of prostate cancer and the location of the mutation within the gene.
引用
- Nyberg T, Frost D, Barrowdale D, et al. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. Eur Urol. 2019. PMID: 31495749. doi:10.1016/j.eururo.2019.08.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。